$SIRO (Sirona Dental Systems Inc.)

$SIRO {{ '2016-01-12T07:41:15+0000' | timeago}} • Announcement

Dental equipment makers $XRAY and $SIRO said that shareholders of each company have approved all proposals necessary to complete the merger-of-equals transaction. The companies expect to complete the merger in 1Q16.

$BMY {{ '2017-07-27T12:44:31+0000' | timeago}} • Infographic

$BMY Bristol-Myers Squibb Co Earnings AlphaGraphics: Q2 2017 highlights

$CYH {{ '2017-07-27T12:33:35+0000' | timeago}} • Announcement

Hospital operator $CYH said it expects 2Q17 operating revenue to be about $4.1Bil, lower than $4.6Bil recorded last year. The company sees a net loss of $137MM or $1.22 per share for the quarter, compared to the $1.431Bil loss recorded in 2Q16. Adjusted EBITDA is estimated at $435MM, compared to $563MM a year earlier.

$BMY {{ '2017-07-27T11:32:39+0000' | timeago}} • Announcement

$BMY updated its FY17 GAAP EPS guidance range to $2.66-2.76 and raised the lower end of its non-GAAP EPS guidance range to $2.90-3.00, as the pharma giant posted 2Q17 results.

$ALXN {{ '2017-07-27T11:31:03+0000' | timeago}} • Announcement

$ALXN's sale of its flagship drug Soliris was $814MM in 2Q17, compared to $701MM in the prior-year period, representing a 16% increase. Soliris volume increased 18% YoY. Soliris is primarily used to treat a rare disorder that destroys red blood cells.

$BMY {{ '2017-07-27T11:30:29+0000' | timeago}} • Announcement

As $BMY posted its 2Q17 results, it also announced that the European Commission (EC) approved its drug ORENCIA alone or in combination with methotrexate for the treatment of active Psoriatic Arthritis in certain adult patients.

$BMY {{ '2017-07-27T11:28:03+0000' | timeago}} • Announcement

A 31% surge in R&D expenses of $1.7Bil in 2Q17 saw $BMY's net attributable earnings slumping 24% to $916MM, even as revenue rose 6% to $5.1Bil. Diluted EPS slipped 19% to $0.56, while non-GAAP diluted EPS rose 7% to $0.74.

$ALXN {{ '2017-07-27T11:20:47+0000' | timeago}} • Announcement

$ALXN raised its 2017 forecast for both GAAP and non-GAAP revenue to $3.45-3.525Bil, vs the prior guidance of $3.40-3.50Bil. Non-GAAP EPS projection for this period was also raised to $5.40-5.55, compared to the prior guidance of $5.10-5.30. Meanwhile, the company now sees GAAP EPS in the range of $2.82-3.12.

$ALXN {{ '2017-07-27T11:10:27+0000' | timeago}} • Announcement

Global biopharmaceutical company $ALXN reported 21% jump in revenue in 2Q17 to $912MM. The revenue reflected a benefit of about $35MM due to favorable timing of orders compared to its prior forecast. Net income rose to $165MM, or $0.73 per share, from $120MM, or $0.53 per share, a year ago. On an adjusted basis, $ALXN earned $1.56, up 38% YoY.

$VRTX {{ '2017-07-26T20:38:11+0000' | timeago}} • Announcement

$VRTX also reviewed its recent progress toward treating all people with cystic fibrosis, including the completion of an asset purchase agreement with Concert Pharmaceuticals for worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis.

$VRTX {{ '2017-07-26T20:36:21+0000' | timeago}} • Announcement

$VRTX lifted 2017 non-GAAP combined research & development and selling, general & administrative expenses outlook to $1.33-1.36Bil from $1.25-1.30Bil, and GAAP combined R&D and SG&A expenses estimate to $1.79-1.92 from $1.55-1.70. The updated forecast reflects the progression of the company's cystic fibrosis portfolio.

$VRTX {{ '2017-07-26T20:33:48+0000' | timeago}} • Announcement

$VRTX expects 2017 total cystic fibrosis product revenue of $1.84-2.07Bil, comprised of Orkambi and Kalydeco product revenues. $VRTX still expects 2017 product revenue for Orkambi of $1.1-1.3Bil and for Kalydeco of $740-770MM.

$VRTX {{ '2017-07-26T20:30:18+0000' | timeago}} • Announcement

$VRTX's net product revenues from cystic fibrosis therapy Orkambi for 2Q17 increased to $324.4MM from $245.5MM last year. This was primarily driven by the continued uptake in the medicine globally and additional uptake in people with cystic fibrosis ages 6 to 11 in the U.S., where approval was received in September 2016.

$VRTX {{ '2017-07-26T20:26:38+0000' | timeago}} • Announcement

$VRTX reported net income for 2Q17 of $31.17MM or $0.07 per share compared to a loss of $64.53MM or $0.26 per share last year. This swing in results was driven by higher revenue as well as a decline in interest expenses. Revenue grew to $544.14MM from $431.61MM. Non-GAAP EPS increased to $0.39 from $0.24.

$BAX {{ '2017-07-26T12:58:04+0000' | timeago}} • Announcement

$BAX anticipates 2020 adjusted EPS of $3.25-3.40. $BAX also lifted its cash flow expectations for 2020 and now sees operating cash flow of about $2.65Bil. Capital expenditures are expected to total $650MM in 2020, resulting in free cash flow generation of about $2Bil, an increase of $250MM versus prior guidance.

$BAX {{ '2017-07-26T12:56:58+0000' | timeago}} • Announcement

As a result of ongoing business transformation efforts designed to accelerate performance, $BAX lifted its 2020 financial outlook. $BAX expects sales growth of 4% on a compounded annual basis from 2016 to 20202 and now sees adjusted operating margin in 2020 of about 20% as compared to previous guidance of 17-18%.

$BAX {{ '2017-07-26T12:55:25+0000' | timeago}} • Announcement

$BAX expects 3Q17 sales growth of about 4% on a reported basis, about 5% on a constant currency basis and about 6% operationally. The company expects earnings from continuing operations, before special items, of $0.58-0.60 per diluted share.

$BAX {{ '2017-07-26T12:54:23+0000' | timeago}} • Announcement

$BAX lifted 2017 EPS from continuing operations, before special items, guidance to $2.34-2.40 from $2.20-2.28. This guidance assumes the closure of the company's proposed acquisition of Claris Injectables, to be complete by the end of July 2017.

$BAX {{ '2017-07-26T12:52:56+0000' | timeago}} • Announcement

$BAX now expects 2017 sales growth of about 3% on a reported basis, about 4% on constant currency basis and about 5% operationally. Previously, the company had predicted sales growth of about 1-2% on a reported basis or 2-3% on a constant currency basis.

$BAX {{ '2017-07-26T12:46:39+0000' | timeago}} • Announcement

$BAX's renal sales totaled $968MM, comparable to the prior year on reported basis and up 3% on both a constant currency basis and operational basis. Growth was driven by increased sales for in-center hemodialysis (HD) products in the US, international acute renal care sales and global sales of peritoneal dialysis (PD) therapies.

$BAX {{ '2017-07-26T12:45:36+0000' | timeago}} • Announcement

$BAX's global sales for Hospital Products totaled $1.6Bil in 2Q17, rising 1% on reported, 2% on constant currency and 4% operationally. This was driven by continued strength in US fluid systems business, favorable demand for parenteral nutrition therapies and pre-mixed injectable, as well as for select anesthesia and critical care products.

Recent Transcripts

VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, July 26 2017 - 9:15pm
VAR (Varian Medical Systems, Inc.)
Wednesday, July 26 2017 - 9:00pm
BAX (Baxter International Inc.)
Wednesday, July 26 2017 - 12:30pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
PHG (Koninklijke Philips N.V)
Monday, July 24 2017 - 8:00am
GE (General Electric Company)
Friday, July 21 2017 - 12:30pm
FARO (FARO Technologies Inc.)
Wednesday, May 10 2017 - 12:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
OPK (Opko Health, Inc.)
Tuesday, May 9 2017 - 8:30pm
XRAY (DENTSPLY International Inc.)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
HAE (Haemonetics Corporation)
Monday, May 8 2017 - 12:00pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
CYH (Community Health Systems, Inc.)
Tuesday, May 2 2017 - 4:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
ALGN (Align Technology Inc.)
Thursday, April 27 2017 - 8:30pm
RMD (ResMed Inc.)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, April 27 2017 - 2:00pm

AlphaGraphics you may like